Hasan Huseyin Uckan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hasan Huseyin Uckan has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Gökçe Turan
Department of Obstetrics and Gynecology, School of Medicine, Gazi University, Ankara, Turkey
2 shared publications - Anil Erturk
Department of Obstetrics and Gynecology, Hacettepe Universitesi Tip Fakultesi, Hacettepe University, Ankara, Turkey
1 shared publication - Atakan Tanacan
Perinatology Department Ankara Bilkent City Hospital Ankara Turkey
1 shared publication - Ayla Eser
Gazi University, Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey
1 shared publication - Betul Tas
University of Health Sciences, Bagcilar Training and Research Hospital
1 shared publication - Cem Terece
Department of Obstetrics and Gynecology, Balikesir Ataturk City Hospital, Balikesir 10100, Turkey
1 shared publication
Latest Publications
- 3 February 2023
- Published by Elsevier in Journal of Forensic and Legal Medicine
- Vol. 95, 102491
The analysis of pregnancies terminated before and after the limit of viability: A medicolegal view
- 3 February 2023
- Published by Elsevier in Journal of Forensic and Legal Medicine
- Vol. 95, 102491
The analysis of pregnancies terminated before and after the limit of viability: A medicolegal view
- Open Access
- 2 December 2022
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 38 (12) , 1104-1108
Evaluation of androgen-dependent skin findings of polycystic ovary syndrome (PCOS)
The purpose of the study was to investigate the biochemical and metabolic abnormalities related to the cutaneous characteristics of PCOS.Patients diagnosed with PCOS were included in the study. Dem...
- 2 December 2022
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 38 (12) , 1104-1108
Open AccessEvaluation of androgen-dependent skin findings of polycystic ovary syndrome (PCOS)
The purpose of the study was to investigate the biochemical and metabolic abnormalities related to the cutaneous characteristics of PCOS.Patients diagnosed with PCOS were included in the study. Dem...
- 1 September 2019
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 20 (3) , 170-177
Congenital central nervous system anomalies: Ten-year single center experience on a challenging issue in perinatal medicine
Objective: Our goal was to highlight the prenatal diagnosis and management of central nervous system (CNS) anomalies through sharing our clinic's experience. Methods: We evaluated prenatal findings and postnatal outcomes of neonates who had a CNS anomaly diagnosis in our clinic over a ten-year period. A total of 183 cases with various CNS anomalies were included in the study. Birth or termination preferences of mothers were recorded in all cases, and postnatal diagnosis concordance and prognosis after surgical procedures were evaluated in mothers who chose to continue the pregnancy. Results: The mean maternal age was 28.2 +/- 5.5 years, mean gravida was 2.2 +/- 1.3, and the mean gestational age at diagnosis was 30.5 +/- 5.5 weeks. Seventy-five out of 183 (41%) patients chose to terminate their pregnancy. Twenty babies (26.6%) in the termination of pregnancy group had additional anomalies. One hundred eight patients gave birth at our institution. The mean birth weight was 3060 +/- 647.5 g, the mean gestational week at delivery was 37.9 +/- 1.7 weeks, and mean APGAR score (5th minute) was 8.8 +/- 2.3. Four neonates died on the postpartum first day. The postnatal diagnosis of 60 of the 108 (55.5%) patients who gave birth was concordant with the prenatal diagnosis, and 32 of the 108 (29.6%) babies underwent surgical interventions. Conclusion: CNS anomalies have a broad spectrum and variable prognoses. This study highlights the limitations of prenatal diagnoses, and the need for parents to have this information in order to determine the course of their pregnancy and prepare themselves for the postnatal challenging treatment/rehabilitation process.
- 1 September 2019
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 20 (3) , 170-177
Congenital central nervous system anomalies: Ten-year single center experience on a challenging issue in perinatal medicine
Objective: Our goal was to highlight the prenatal diagnosis and management of central nervous system (CNS) anomalies through sharing our clinic's experience. Methods: We evaluated prenatal findings and postnatal outcomes of neonates who had a CNS anomaly diagnosis in our clinic over a ten-year period. A total of 183 cases with various CNS anomalies were included in the study. Birth or termination preferences of mothers were recorded in all cases, and postnatal diagnosis concordance and prognosis after surgical procedures were evaluated in mothers who chose to continue the pregnancy. Results: The mean maternal age was 28.2 +/- 5.5 years, mean gravida was 2.2 +/- 1.3, and the mean gestational age at diagnosis was 30.5 +/- 5.5 weeks. Seventy-five out of 183 (41%) patients chose to terminate their pregnancy. Twenty babies (26.6%) in the termination of pregnancy group had additional anomalies. One hundred eight patients gave birth at our institution. The mean birth weight was 3060 +/- 647.5 g, the mean gestational week at delivery was 37.9 +/- 1.7 weeks, and mean APGAR score (5th minute) was 8.8 +/- 2.3. Four neonates died on the postpartum first day. The postnatal diagnosis of 60 of the 108 (55.5%) patients who gave birth was concordant with the prenatal diagnosis, and 32 of the 108 (29.6%) babies underwent surgical interventions. Conclusion: CNS anomalies have a broad spectrum and variable prognoses. This study highlights the limitations of prenatal diagnoses, and the need for parents to have this information in order to determine the course of their pregnancy and prepare themselves for the postnatal challenging treatment/rehabilitation process.
- 2 September 2017
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 296 (5) , 979-987
What is the impact of stromal microinvasion on oncologic outcomes in borderline ovarian tumors? A multicenter case–control study
Purpose To investigate clinicopathological characteristics and oncological outcome of women with microinvasive BOTs. Methods A retrospective multicenter case–control study was conducted on 902 patients with BOT, who underwent surgery from January 2002 to December 2015 at six participating gynecologic oncology centers from Turkey. Among 902 patients, 69 had microinvasive BOT. For every patient with microinvasive BOT, two controls were randomly selected from another database based on decade of age and stage of disease at diagnosis. The clinical–pathological characteristics and oncological outcomes were compared between BOT patients with and without stromal microinvasion. Risk factors for poor oncological outcomes were investigated in a multivariate analysis model. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan–Meier method. Results Patients with microinvasive BOT had a significantly higher rate of recurrence than patients without microinvasive BOT (17.4 vs 7.8%, OR 3.55, %95 CI 1.091–11.59, p = 0.03). Stage at diagnosis (stage I versus II/III) and type of surgery (cystectomy versus others) were found as other significant prognostic factors for recurrence in multivariate analysis (OR 8.63, %95 CI 2.48–29.9, p = 0.001 and OR 19.4, %95 CI 3.59–105.6, p = 0.001, respectively). Stromal microinvasion was found as a prognostic factor for significantly shorter DFS (26.7 vs 11.9 months, p = 0.031, log rank). However, there was no significant difference in OS between two groups (p = 0.99, log rank). Conclusion Stromal microinvasion is significantly associated with decreased DFS. In addition, our study confirms that the risk of recurrence is higher in patients with microinvasive BOT.
- 2 September 2017
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 296 (5) , 979-987
What is the impact of stromal microinvasion on oncologic outcomes in borderline ovarian tumors? A multicenter case–control study
Purpose To investigate clinicopathological characteristics and oncological outcome of women with microinvasive BOTs. Methods A retrospective multicenter case–control study was conducted on 902 patients with BOT, who underwent surgery from January 2002 to December 2015 at six participating gynecologic oncology centers from Turkey. Among 902 patients, 69 had microinvasive BOT. For every patient with microinvasive BOT, two controls were randomly selected from another database based on decade of age and stage of disease at diagnosis. The clinical–pathological characteristics and oncological outcomes were compared between BOT patients with and without stromal microinvasion. Risk factors for poor oncological outcomes were investigated in a multivariate analysis model. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan–Meier method. Results Patients with microinvasive BOT had a significantly higher rate of recurrence than patients without microinvasive BOT (17.4 vs 7.8%, OR 3.55, %95 CI 1.091–11.59, p = 0.03). Stage at diagnosis (stage I versus II/III) and type of surgery (cystectomy versus others) were found as other significant prognostic factors for recurrence in multivariate analysis (OR 8.63, %95 CI 2.48–29.9, p = 0.001 and OR 19.4, %95 CI 3.59–105.6, p = 0.001, respectively). Stromal microinvasion was found as a prognostic factor for significantly shorter DFS (26.7 vs 11.9 months, p = 0.031, log rank). However, there was no significant difference in OS between two groups (p = 0.99, log rank). Conclusion Stromal microinvasion is significantly associated with decreased DFS. In addition, our study confirms that the risk of recurrence is higher in patients with microinvasive BOT.